Bowing to Market Shifts and Sales Missteps, Harvard Bio to Jettison Cap Equipment Biz | GenomeWeb

Reeling from a shrunken market, sales missteps, and a restructuring that has not translated into the expected results, Harvard Bioscience has decided to sell its capital equipment business.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.